The estimated Net Worth of Shreeram Aradhye is at least 3.95 百万$ dollars as of 15 December 2021. Shreeram Aradhye owns over 2,837 units of Axcella Health Inc stock worth over 35,751$ and over the last 5 years he sold AXLA stock worth over 0$. In addition, he makes 3,911,720$ as Executive Vice President、 Chief Development Officer at Axcella Health Inc.
Shreeram has made over 2 trades of the Axcella Health Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 2,837 units of AXLA stock worth 12,993$ on 15 December 2021.
The largest trade he's ever made was exercising 7,025 units of Axcella Health Inc stock on 15 September 2021 worth over 32,175$. On average, Shreeram trades about 1,233 units every 11 days since 2019. As of 15 December 2021 he still owns at least 7,806 units of Axcella Health Inc stock.
You can see the complete history of Shreeram Aradhye stock trades at the bottom of the page.
Dr. Shreeram Aradhye M.D. serves as Executive Vice President, Chief Development Officer of the Company. Prior to joining us, Dr. Aradhye built an accomplished career at Novartis Pharmaceuticals Corporation. For over two decades, he served in multiple leadership roles of increasing responsibility in Development and Medical Affairs, across multiple therapeutic areas and geographies. In his most recent role as CMO of Novartis, he was a member of the Global Pharmaceuticals Executive Committee responsible for over $20 billion in worldwide business, provided medical expertise on portfolio strategy and led governance of medical activities worldwide. Dr. Aradhye was also a Member of the Development Committee of Novartis that oversaw global development activities across its portfolio. In previous roles at Novartis and Sandoz, he led the clinical development program for Gilenya® in MS, provided functional leadership for clinical development and medical affairs teams working on novel and biosimilar medicines across multiple therapeutic areas and headed Global Development for Neuroscience, where he oversaw a portfolio of programs in MS, Alzheimer's Disease, neuropathic pain, muscle disease and migraine. Prior to industry, Dr. Aradhye was Assistant Professor of Medicine and a transplant nephrologist at the University of Pennsylvania.
As the Executive Vice President、 Chief Development Officer of Axcella Health Inc, the total compensation of Shreeram Aradhye at Axcella Health Inc is 3,911,720$. There are no executives at Axcella Health Inc getting paid more.
Shreeram Aradhye is 57, he's been the Executive Vice President、 Chief Development Officer of Axcella Health Inc since 2019. There are 4 older and 11 younger executives at Axcella Health Inc. The oldest executive at Axcella Health Inc is Catherine Sohn, 67, who is the Independent Director.
Shreeram's mailing address filed with the SEC is C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON, MA, 02421.
Over the last 6 years, insiders at Axcella Health Inc have traded over 32,393$ worth of Axcella Health Inc stock and bought 29,966,648 units worth 79,278,835$ . The most active insiders traders include Ventures Fund Iv General Pa...、Ventures Fund Iv General Pa...、Des Produits Nestle S.A.Nes.... On average, Axcella Health Inc executives and independent directors trade stock every 31 days with the average trade being worth of 3,073,698$. The most recent stock trade was executed by Margaret Koziel on 1 March 2023, trading 679 units of AXLA stock currently worth 394$.
axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.
Axcella Health Inc executives and other stock owners filed with the SEC include: